原发性肝癌患者红细胞免疫粘附肿瘤细胞能力与红细胞CR1基因型及活性相关性分析

目的　研究原发性肝癌患者红细胞免疫粘附肿瘤细胞能力与红细胞ＣＲ１ 基因组密度多态性及活性的相关性。方法　采用ＰＣＲ 和Ｈｉｎｄ Ⅲ酶切技术测定红细胞ＣＲ１ 基因组密度多态性变化，同时用ＥＬＩＳＡ 和肿瘤红细胞花环试验测定红细胞ＣＲ１ 活性，并进行比较。结果　原发性肝癌患者红细胞ＣＲ１ 基因型点突变比率（４３－６ ％ ） 明显上升，与正常人（２０ ％ ） 相比，差异有显著性（ Ｐ＜０－０５） ；原发性肝癌患者３ 种ＣＲ１ 基因型的红细胞ＣＲ１ 活性都明显低于正常人（ Ｐ＜ ０－０１ 或 Ｐ＜０－０５） 。活性变化也不同。结论　原发性肝癌患者红细胞ＣＲ１ 活性及免疫粘附肿瘤细胞能力下降可分为三种不同类型，即原发型、获得型和混合型。

Studies on relationships between ability of red cell adhering to tumor cells and CR1 activity and CR1 genomic density polymorphism on red cell in patients with primary hepatocarcinoma

Objective To study the relationship between ability of red cell adhering to tumor cells and CR1 activity and CR1 genomic density polymorphism on red cell in patients with primary hepatocarcinoma. Methods Using PCR RFLP, ELISA and tumor erythrocyte rose test. We detected the ECR1 genomic density polymorphism and CR1 activity and ability of red cell adhering to tumor cells of 94 patients with primary hepatocarcinoma (PHC) and 80 normal individuals, respectively. Results The spot mutation rate (43.6%) of ECR1 genomic density gene in patients with PHC was higher than that (20%) in normal people ( P <0.05). Ability of three CR1 gene type erythrocytes adhering to tumor cells in patients with PHC significantly was lower than that in normal with CR1 same gene type ( P <0.01 or P <0.05). Conclusions There are three types of decrement in ability of erythrocytes adhering to tumor cells: primary type, acquired type and mixture type.